These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6327657)

  • 1. Chemotherapy of cognitive disorders in geriatric subjects.
    Goodnick P; Gershon S
    J Clin Psychiatry; 1984 May; 45(5):196-209. PubMed ID: 6327657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Psychopharmacologic treatment of cognitive function disorders in aging persons: current possibilities].
    Jolles J; Verhoeven WM
    Tijdschr Gerontol Geriatr; 1984 Aug; 15(4):139-50. PubMed ID: 6091299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Senile dementia of the Alzheimer type.
    Erwin WG
    Clin Pharm; 1984; 3(5):497-504. PubMed ID: 6149031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternatives in the treatment of memory loss in patients with Alzheimer's disease.
    Volger BW
    Clin Pharm; 1991 Jun; 10(6):447-56. PubMed ID: 2065522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the neurochemistry of Alzheimer disease.
    Davies P
    Adv Neurol; 1983; 38():75-86. PubMed ID: 6137134
    [No Abstract]   [Full Text] [Related]  

  • 6. An overview of pharmacologic treatment of cognitive decline in the aged.
    Reisberg B; Ferris SH; Gershon S
    Am J Psychiatry; 1981 May; 138(5):593-600. PubMed ID: 7015883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical approaches to the treatment of senile dementia.
    Growdon JH; Corkin S
    Proc Annu Meet Am Psychopathol Assoc; 1980; 69():281-96. PubMed ID: 7413654
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease.
    Tsang SW; Lai MK; Kirvell S; Francis PT; Esiri MM; Hope T; Chen CP; Wong PT
    Neurobiol Aging; 2006 Sep; 27(9):1216-23. PubMed ID: 16129514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild cognitive impairment and preclinical Alzheimer's disease.
    Morris JC
    Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piracetam: novelty in a unique mode of action.
    Müller WE; Eckert GP; Eckert A
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():2-9. PubMed ID: 10338102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral physostigmine and lecithin improve memory in Alzheimer's disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS; Davies P
    Psychopharmacol Bull; 1983; 19(3):454-6. PubMed ID: 6635124
    [No Abstract]   [Full Text] [Related]  

  • 17. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild cognitive impairment: transition between aging and Alzheimer's disease.
    Petersen RC
    Neurologia; 2000 Mar; 15(3):93-101. PubMed ID: 10846869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
    Reger MA; Henderson ST; Hale C; Cholerton B; Baker LD; Watson GS; Hyde K; Chapman D; Craft S
    Neurobiol Aging; 2004 Mar; 25(3):311-4. PubMed ID: 15123336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.